PubMed · 16259229
Lasofoxifene (Pfizer).
Abstract
Pfizer is developing lasofoxifene, an oral naphthalene derivative selective estrogen receptor modulator identified under a collaboration with Ligand, for the treatment of osteoporosis and vaginal atrophy. In August 2004, Pfizer submitted a New Drug Application to the Food and Drug Administration (FDA) seeking approval of lasofoxifene for the treatment of osteoporosis; however, in September 2005, the FDA issued a non-approvable letter.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Luigi Gennari. 2005. Lasofoxifene (Pfizer).. https://pubmed.ncbi.nlm.nih.gov/16259229/
Cite the original work for its findings. Save a collection to share your selection of sources.